Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?
Details
Download: 35570855_BIB_37C45F4E9C6B.pdf (1341.61 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_37C45F4E9C6B
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?
Journal
Current research in pharmacology and drug discovery
ISSN
2590-2571 (Electronic)
ISSN-L
2590-2571
Publication state
Published
Issued date
2022
Peer-reviewed
Oui
Volume
3
Pages
100104
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Publication Status: epublish
Abstract
The number of available biological therapies have doubled over the last 10 years and the arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the development of small molecules. As a result of this vast landscape of treatment, positioning advanced therapies (according to clinical situation, efficacy and safety) is of paramount importance to providing personalized, appropriate IBD treatment. In this publication the recent available literature is summarized for practical integration into clinical practice including comparative efficacy data, patient and disease demographics. We refer to recent publications and expert opinion in order to facilitate the decision making process of positioning biologicals IBD treatment.
Keywords
Adalimumab, Biological therapy, Infliximab, Monoclonal antibodies, Ustekinumab, Vedolizumab
Pubmed
Open Access
Yes
Create date
23/05/2022 13:49
Last modification date
09/08/2024 15:57